SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 190.43-0.7%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Machaon who wrote (28242)2/18/1999 11:44:00 AM
From: Henry Niman  Read Replies (1) of 32384
 
LGND is seeking to license out the sale of Targretin into areas where they do not have a presence (LGND is in the US, Canada, Europe and maybe Australia).

LGND can charge much more for a cancer treatment than a diabetes treatment, which would complicate distribution agreements because pricing of initial cancer applications could be impacted by future diabetes approvals (if Targretin oral cost $20 per pill for cancer and $2 per pill for diabetes, it would be harder to sell the $20 pills).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News